| P2093 | author name string | Rafael Cantón | |
| | María Isabel Morosini | |
| P2860 | cites work | Bacterial persistence: a model of survival in changing environments | Q24544968 |
| | Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells | Q24682375 |
| | Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin | Q28268465 |
| | Bacterial persistence as a phenotypic switch | Q29618111 |
| | Regulation of phenotypic variability by a threshold-based mechanism underlies bacterial persistence | Q30495567 |
| | Is bacterial persistence a social trait? | Q33294723 |
| | Phenotypic tolerance: antibiotic enrichment of noninherited resistance in bacterial populations | Q33722011 |
| | Heteroresistance to vancomycin in Enterococcus faecium | Q33973499 |
| | Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin | Q34107062 |
| | Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections | Q34303042 |
| | Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia | Q34396414 |
| | Clonal spread of Staphylococcus aureus heterogeneously resistant to vancomycin in a university hospital in Korea. | Q34455373 |
| | Phenotypic variation in bacteria: the role of feedback regulation | Q34502643 |
| | Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). | Q34691938 |
| | Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 |
| | Factors influencing methicillin resistance in staphylococci | Q34791183 |
| | Bacterial persistence: some new insights into an old phenomenon | Q34932825 |
| | The importance of being persistent: heterogeneity of bacterial populations under antibiotic stress. | Q34941745 |
| | Antibiotic tolerance in pneumococci | Q34975929 |
| | Widespread dissemination in The Netherlands of the epidemic berlin methicillin-resistant Staphylococcus aureus clone with low-level resistance to oxacillin | Q35718031 |
| | Heteroresistance to penicillin in Streptococcus pneumoniae | Q35944300 |
| | Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy | Q36328976 |
| | Non-inherited antibiotic resistance. | Q36508695 |
| | Methicillin-resistant staphylococci | Q36632851 |
| | Microbial phenotypic heterogeneity and antibiotic tolerance. | Q36704124 |
| | Role of Autolysins in the Killing of Bacteria by Some Bactericidal Antibiotics | Q36774337 |
| | Vancomycin: does it still have a role as an antistaphylococcal agent? | Q36839712 |
| | Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus | Q36903680 |
| | Combating bacteria and drug resistance by inhibiting mechanisms of persistence and adaptation. | Q36914997 |
| | Prevalence, molecular epidemiology, and clinical significance of heterogeneous glycopeptide-intermediate Staphylococcus aureus in liver transplant recipients. | Q37058087 |
| | Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains | Q37156698 |
| | Antibiotic resistance of bacterial biofilms | Q37690946 |
| | Antibiotic tolerance among clinical isolates of bacteria | Q39750871 |
| | Problems in in vitro determination of antibiotic tolerance in clinical isolates | Q39753950 |
| | Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus | Q40166227 |
| | Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus | Q40542104 |
| | Characteristics of meropenem heteroresistance in Klebsiella pneumoniae carbapenemase (KPC)-producing clinical isolates of K. pneumoniae | Q41818495 |
| | Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin | Q42042890 |
| | Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm | Q42111239 |
| | Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus. | Q42112490 |
| | Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm | Q42845932 |
| | Heteroresistance to glycopeptides in Italian meticillin-resistant Staphylococcus aureus (MRSA) isolates. | Q42930819 |
| | Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia | Q43014200 |
| | Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years | Q43117809 |
| | Efficacy of vancomycin and daptomycin against Staphylococcus aureus isolates collected over 29 years | Q43131311 |
| | Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility | Q43433837 |
| | Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia | Q44883937 |
| | Resonant activation: a strategy against bacterial persistence | Q44954151 |
| | Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy | Q44959085 |
| | Role of persisters and small-colony variants in antibiotic resistance of planktonic and biofilm-associated Staphylococcus aureus: an in vitro study. | Q45968330 |
| | Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q46826194 |
| | Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus | Q46838740 |
| | Heteroresistance: a concern of increasing clinical significance? | Q46841479 |
| | Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. | Q46879391 |
| | Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia | Q46933141 |
| | Modelling protection from antimicrobial agents in biofilms through the formation of persister cells | Q48505319 |
| | Incorporating toxin hypothesis into a mathematical model of persister formation and dynamics. | Q51911970 |
| | Antibiotic treatment in vitro of phenotypically tolerant bacterial populations. | Q51928788 |
| | Hetero-resistance: an under-recognised confounder in diagnosis and therapy? | Q53984568 |
| | Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. | Q54069940 |
| | Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. | Q54095666 |
| | Glycopeptide tolerance in Staphylococcus aureus. | Q54125104 |
| | Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. | Q55067143 |
| | Biofilms | Q56080242 |
| | TREATMENT OF STAPHYLOCOCCAL INFECTIONS WITH PENICILLIN BY INTERMITTENT STERILISATION | Q56566176 |
| | Antibiotic Tolerance Among Clinical Isolates of Bacteria | Q57077300 |
| | The activity of daptomycin against wild-type Staphylococcus aureus and strains with reduced susceptibility to vancomycin | Q80124611 |
| | An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus | Q83230645 |
| P407 | language of work or name | Spanish | Q1321 |
| P921 | main subject | gram-positive bacteria | Q857288 |
| P304 | page(s) | 16-22 | |
| P577 | publication date | 2010-12-01 | |
| P1433 | published in | Medicina clínica | Q26854009 |
| P1476 | title | Tolerance and heteroresistance in Gram-positive microorganisms | |
| P478 | volume | 135 Suppl 3 | |